

RETINA 360 WORKBOOK



IN FOCUS: DIABETIC EYE DISEASE CLINICAL PEARLS

Use of Second-Generation Retinal Therapies
in the Real World

FACULTY



Mohsin H. Ali, MD
Retina Group of Washington
Fairfax, VA



Arthi G. Venkat, MD, MS
Assistant Professor
Associate Residency Program Director
University of Virginia School of Medicine
Charlottesville, VA

This activity is supported by an independent educational grant from Regeneron.

Use of Second-Generation Retinal Therapies in the Real World

Mohsin H. Ali, MD, and Arthi G. Venkat, MD, MS

Watch Now: <https://evolvemeded.com/segment/29865/>





CASE HIGHLIGHTS

- Second-generation drugs can provide a buffer for patients who may not be able to maintain strict follow-up schedules, allowing for longer treatment intervals.
- Factors to consider when initiating second-generation therapy include the minimum treatment interval, treatment history, and potential step therapy requirements.
- Extending treatment intervals can improve patient compliance, comfort, and quality of life, especially for working-age patients.
- Practical considerations such as insurance coverage and administrative burden may impact the choice between second-generation therapies.

“So about 40% of my patients will receive aflibercept 8 mg and about 20% of my patients will receive aflibercept 2 mg. And about another 20% will receive faricimab and the remaining 20% are going to fall into the category of bevacizumab or compounded medications or biosimilars.”

MOHSIN H. ALI, MD

NOTES



VIDEO CASE:
FINAL OCT:
CENTRAL
FOVEAL
THICKNESS OD
268, OS 300.